Mannitol Cream for Post Herpetic Neuralgia (MannitolPHN)

October 21, 2018 updated by: Helene Bertrand, University of British Columbia

Mannitol Cream in the Treatment of Post-herpeticNeuralgia;a Randomized Placebo-Controlled Crossover Pilot Study

30% mannitol cream has shown its ability to reduce the activation of the Capsaicin (TRPV1) (Transient Receptor Potential Vanilloid 1) receptor, a likely cause of the pain of post-herpetic neuralgia (PHN). This randomized placebo-controlled crossover study compares PHN pain one week before, for one week on the randomly assigned mannitol versus placebo cream and, after a three day washout, for one week on the other cream. Following this crossover study, participants receive mannitol cream for three months. Pain levels will be checked to assess whether continued use of this cream significantly reduces the pain levels associated with PHN. If pain persists beyond 3 months, participants will be offered mannitol and menthol cream for one month following which their pain levels will be checked.

Study Overview

Status

Completed

Detailed Description

Pain levels: 0 to 10 Numerical Rating Scale (NRS), medication and alcohol intake will be checked daily for one week prior to randomization in 20 participants with post herpetic neuralgia, lasting more than three months. Following this 10 will be randomized to apply 30% mannitol in vehicle cream and 10 to apply vehicle cream alone for one week during which daily pain levels and use of medication and alcohol will be measured together with the mode of application (rubbing in or applying it to cling wrap then applying the cream coated cling wrap to the skin in cases of severe allodynia). After a three day washout period, they will be given the cream they did not receive previously for one week. The same variables will be recorded daily. The data collected in the first 24 days will be used to generate a power analysis. Following this, all subjects will receive the 30% mannitol cream to apply for three months. Their pain levels, medication intake and method of application will be measured once a month for three months. T-tests will compare the pain levels for mannitol and placebo users before and after one week of the use of each cream to see if the mannitol cream provides better short term pain relief than placebo. Repeated measures ANOVA (Analysis Of VAriance) will compare pain levels before using the mannitol cream and monthly for three months to assess the long-term effects of mannitol cream. Variables collected at each visit, which will not be used for statistical purposes in the current very small pilot project but may be used in a later study, include: application method, effect and side effects of the cream, medication and alcohol use, PHQ - 9 (Personal Health Questionnaire, 9 questions), and questions from the brief pain inventory score. At three months, a satisfaction score will be added to the database. If pain persists beyond 3 months, participants will be offered mannitol and menthol cream for one month, following which their pain levels, PHQ - 9 and brief pain inventory scores will be checked.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • British Columbia
      • North Vancouver, British Columbia, Canada, V7M 2K2
        • Dr. Helene Bertrand Inc.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

  1. - Suffering from post-herpetic neuralgia on the trunk or the extremities for at least three months.
  2. - Maximum daily pain score greater than or equal to 5/10.
  3. - Having failed to improve with at least one neuropathic pain medication.

4- Able and willing to fill a fluid survey NRS pain scale and a medication intake questionnaire daily, preferably online but on paper, if unable, for the first 24 days of the study, then once a month for three months..

5 - Preferably have access to someone who can apply cream to their back if they have pain in the back and cannot reach the area.

6 - If that is not possible, ability to apply the cream to their own back, using an applicator which will be supplied.

Exclusion Criteria:

  1. Allergies to any of the ingredients of the cream
  2. Open lesions or abrasions on the skin where the cream will be applied
  3. Using corticosteroids
  4. Unwilling to stop using other topical products (creams or patches) for the treatment of post-herpetic neuralgia
  5. Pregnant, breast-feeding or not using birth control
  6. Suffering from severe chronic pain from a cause other than post-herpetic neuralgia

    -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: mannitol in vehicle cream /vehicle cream
one week on the mannitol cream (mannitol 30% in vehicle cream), a 3 day washout period, and one week on the placebo cream (vehicle cream alone). To be applied over the painful area as needed for pain. Usual frequency is 2 to 3 times daily.
Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
Other Names:
  • QR cream
  • Mannitol in vehicle cream
Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
Other Names:
  • Vehicle cream
Active Comparator: vehicle cream /mannitol in vehicle cream
one week on the placebo cream (vehicle cream alone), a 3 day washout period, and one week on the mannitol cream (mannitol 30% in vehicle cream).To be applied over the painful area as needed for pain. Usual frequency is unknown.
Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
Other Names:
  • QR cream
  • Mannitol in vehicle cream
Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
Other Names:
  • Vehicle cream

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in worst NRS (Numerical Rating Scale) pain score
Time Frame: Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
In the last 24 hours, how bad was your pain at its worst? No pain 0 1 2 3 4 5 6 7 8 9 10 Worst pain imaginable
Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Change in average NRS (Numerical Rating Scale) pain score
Time Frame: Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
In the last 24 hours, how bad was your pain on average? No pain 0 1 2 3 4 5 6 7 8 9 10 Worst pain imaginable
Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Pain medication intake
Time Frame: Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3,months
Number of pills taken for pain in one day. Will decrease as the pain intensity decreases. Write the number of tablets that you took: 1. Tylenol/acetaminophen______, 2. Anti-inflammatory medication like Advil/ibuprofen, naproxen, diclofenac, Voltaren, Aleve______, 3. Tylenol or ASA (acetylsalicylic acid) plus narcotic like Tylenol 3, or 292 or Tramacet (acetaminophen/tramadol) ______, 4. Narcotic like morphine, hydromorphone/dilaudid, fentanyl, Demerol, tramadol______, 5. Cannabis, marijuana, or pot______, The total in each category will be added to calculate the total number of tablets taken in 24 hours.
Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3,months
Change in Alcohol intake
Time Frame: Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Number of alcoholic drinks in one day. May decrease as the pain intensity decreases. Write down the total number of alcoholic drinks you had in the last 24 hours:how many glasses of wine ______ glasses of hard liquor______ bottles of beer______. The total number of glasses will be recorded.
Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Change in questions from the brief pain inventory score
Time Frame: Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months

The total from the following questions will be recorded to measure how much their pain is interfering with their lives: Circle one number. In the last 24 hours, how much has your pain interfered with your:

General activity:, Mood: Walking ability: Normal work: (includes both work outside the home and housework) Relations with other people: Sleep: Enjoyment of life: Each of these will be scored as follows: does not interfere 0 1 2 3 4 5 6 7 8 9 10 completely interferes. The scores added up. This sum should decrease as the pain decreases.

Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Change in PHQ-9 (Personal health questionnaire, 9 questions) Score
Time Frame: Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Patients will fill the PHQ - 9 score. http://phqscreeners.com/pdfs/02_PHQ-9/English.pdf The sum of the answers from this questionnaire, which is used to measure the degree of depression, may decrease as the pain intensity decreases.
Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Change in Method of cream application
Time Frame: when each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Patients will describe whether they use cling wrap (4), gentle applicator (3) or rubbing in gently (2) or vigourous rubbing (1)
when each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Change in effect and side effects of the cream
Time Frame: Daily for the 14 days, of the crossover study, then at 1,2 and 3 months
How many times did you apply the cream today?_______ Circle one number. How bad was your pain?.. Before you applied the cream? NRS 0-10 1hour after you applied the cream? NRS 0-10 Did the cream relieve your pain? No □ if Yes □ in how many minutes?____ For how many hours was your pain relieved?____ Did you experience a side effect from the cream? No □ if Yes □ What was it?_________________ Any comments?_______________________
Daily for the 14 days, of the crossover study, then at 1,2 and 3 months
Satisfaction from cream use
Time Frame: Three months after use of mannitol cream was started.
How satisfied were you with the use of this cream? Not at all satisfied 0 1 2 3 4 5 6 7 8 9 10 extremely satisfied
Three months after use of mannitol cream was started.
Change in pain score from mannitol cream use to mannitol and menthol cream use
Time Frame: 1st measurement Three months after use of mannitol cream was started 2nd measurement one month after mannitol and menthol cream started
Maximum pain score after 3 months of mannitol cream use compared to maximum pain score after one month of mannitol and menthol cream use
1st measurement Three months after use of mannitol cream was started 2nd measurement one month after mannitol and menthol cream started

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Helene Bertrand, MD, CM, CCFP, University of British Columbia, Department of family practice

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 30, 2015

Primary Completion (Actual)

April 29, 2016

Study Completion (Actual)

April 30, 2017

Study Registration Dates

First Submitted

June 13, 2015

First Submitted That Met QC Criteria

June 24, 2015

First Posted (Estimate)

June 29, 2015

Study Record Updates

Last Update Posted (Actual)

October 23, 2018

Last Update Submitted That Met QC Criteria

October 21, 2018

Last Verified

October 1, 2018

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neuralgia, Postherpetic

Clinical Trials on Mannitol cream

3
Subscribe